Biosimilars Global Market Opportunities And Strategies To 2031

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $5,000	287 Pages	The Business Research Company	July, 2022	BRC17321517

Best Price Guarantee
Price	from $5,000
Length	287 Pages
Publisher	The Business Research Company
Published Date	July, 2022
SKU	BRC17321517

Biosimilars Global Market Opportunities And Strategies To 2031

Biosimilars Global Market Opportunities And Strategies To 2031 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global biosimilars market as it emerges from the COVID-19 shut down.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 12 geographies.
Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market research findings.
Benchmark performance against key competitors.
Utilize the relationships between key data sets for superior strategizing.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis

Description:

Where is the largest and fastest growing market for biosimilars? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The biosimilars market global report from The Business Research Company answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider biosimilars market; and compares it with other markets.

The report covers the following chapters

Introduction and Market Characteristics - Brief introduction to the segmentations covered in the market, definitions and explanations about biosimilars market.

Key Trends - Highlights the major trends shaping the global biosimilars market. This section also highlights likely future developments in the market.

Global Market Size and Growth - Global historic (2016-2021) and forecast (2021-2026), and (2026-2031) market values, and drivers and restraints that support and control the growth of the market in the historic and forecast periods.

Regional Analysis - Historic (2016-2021) and forecast (2021-2026), and (2026-2031) market values and growth and market share comparison by region.

Market Segmentation - Contains the market values (2016-2031) and analysis for for segment by type, and by applications in the market.

Regional Market Size and Growth - Regional market size (2021), historic (2016-2021) and forecast (2021-2026), and (2026-2031) market values, and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.

Competitive Landscape - Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.

Pipeline Analysis - Briefs on the pipeline analysis of biosimilars from the major players in the market.

Key Mergers and Acquisitions - Information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.

Market Opportunities And Strategies - Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.

Conclusions And Recommendations - Includes recommendations for biosimilars providers in terms of product/service offerings, geographic expansion, marketing strategies and target groups.

Appendix - This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Scope

Markets Covered:

1) By Type: Monoclonal Antibodies; Insulin; Erythropoietin; Granulocyte-Colony Stimulating Factor; Other Hormones; Other Types

2) By Application: Oncology; Chronic And Autoimmune Diseases; Growth Hormone Deficiency; Infectious Diseases; Other Applications

Companies Mentioned: Amgen; Pfizer; Novartis AG; Samsung Bioepis Co., Ltd.; Viatris

Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Brazil; France; Germany; UK; Russia

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; biosimilars indicators comparison.

Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

1. Biosimilars Market Executive Summary
2. Table of Contents
3. List of Figures
4. List of Tables
5. Report Structure
6. Introduction and Market Characteristics: 6.1. General Market Definition; 6.2. Summary; 6.3. Market Segmentation By Type; 6.3.1. Monoclonal Antibodies; 6.3.2. Insulin; 6.3.3. Erythropoietin; 6.3.4. Granulocyte-Colony Stimulating Factor; 6.3.5. Other Hormones; 6.3.6. Other Types; 6.4. Market Segmentation By Application; 6.4.1. Oncology; 6.4.2. Chronic and Autoimmune Diseases; 6.4.3. Growth Hormone Deficiency; 6.4.4. Infectious Diseases; 6.4.5. Other Applications
7. Major Market Trends: 7.1. Robust Research & Development; 7.2. Demand For Biosimilars In The Treatment Of Neutropenia; 7.3. Growing Mergers And Acquisitions; 7.4. Revised FDA Regulations To Facilitate Biosimilar Drug Development; 7.5. Large Number Of Strategic Partnerships; 7.6. Increasing Investments In Biosimilars Market; 7.7. Use of Robots and AI
8. Global Market Size And Growth: 8.1. Market Size; 8.2. Historic Market Growth, 2016 – 2021, Value ($ Million); 8.2.1. Market Drivers 2016 – 2021; 8.2.2. Market Restraints 2016 – 2021; 8.3. Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million); 8.3.1. Market Drivers 2021 – 2026; 8.3.2. Market Restraints 2021 – 2026
9. Global Biosimilars Market Segmentation: 9.1. Global Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million); 9.2. Global Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
10. Biosimilars Market, Regional And Country Analysis: 10.1. Global Biosimilars Market, By Region, Historic and Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million); 10.2. Global Biosimilars Market, By Country, Historic and Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
11. Asia-Pacific Market: 11.1.1. Summary; 11.2. Market Overview; 11.2.1. Region Information; 11.2.2. Market Information; 11.2.3. Background Information; 11.2.4. Government Initiatives; 11.2.5. Regulations; 11.2.6. Regulatory Bodies; 11.2.7. Major Associations; 11.2.8. Taxes Levied; 11.2.9. Corporate Tax Structure; 11.2.10. Investments; 11.2.11. Major Companies; 11.3. Asia-Pacific Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million); 11.4. Asia-Pacific Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million); 11.5. Asia-Pacific Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million); 11.6. Asia-Pacific Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million); 11.7. Asia-Pacific Biosimilars Market: Country Analysis; 11.8. China Market; 11.8.1. Summary; 11.9. Market Overview; 11.9.1. Country Information; 11.9.2. Market Information; 11.9.3. Background Information; 11.9.4. Government Initiatives; 11.9.5. Regulations; 11.9.6. Regulatory Bodies; 11.9.7. Major Associations; 11.9.8. Taxes Levied; 11.9.9. Corporate Tax Structure; 11.9.10. Investments; 11.9.11. Major Companies; 11.10. China Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million); 11.11. China Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million); 11.12. China Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million); 11.13. China Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million); 11.14. India Biosimilars Market; 11.15. India Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million); 11.16. India Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million); 11.17. India Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million); 11.18. India Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million); 11.19. Japan Biosimilars Market; 11.20. Japan Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million); 11.21. Japan Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million); 11.22. Japan Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million); 11.23. Japan Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million); 11.24. Australia Biosimilars Market; 11.25. Australia Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million); 11.26. Australia Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million); 11.27. Australia Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million); 11.28. Australia Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million); 11.29. Indonesia Biosimilars Market; 11.30. Indonesia Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million); 11.31. Indonesia Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million); 11.32. Indonesia Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million); 11.33. Indonesia Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million); 11.34. South Korea Biosimilars Market; 11.35. South Korea Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million); 11.36. South Korea Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million); 11.37. South Korea Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million); 11.38. South Korea Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
12. Western Europe Market: 12.1.1. Summary; 12.2. Market Overview; 12.2.1. Region Information; 12.2.2. Market Information; 12.2.3. Background Information; 12.2.4. Government Initiatives; 12.2.5. Regulations; 12.2.6. Regulatory bodies; 12.2.7. Major Associations; 12.2.8. Taxes Levied; 12.2.9. Corporate Tax Structure; 12.2.10. Investments; 12.2.11. Major Companies; 12.3. Western Europe Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million); 12.4. Western Europe Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million); 12.5. Western Europe Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million); 12.6. Western Europe Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million); 12.7. Western Europe Biosimilars Market: Country Analysis; 12.8. UK Biosimilars Market; 12.9. UK Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million); 12.10. UK Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million); 12.11. UK Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million); 12.12. UK Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million); 12.13. Germany Biosimilars Market; 12.14. Germany Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million); 12.15. Germany Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million); 12.16. Germany Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million); 12.17. Germany Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million); 12.18. France Biosimilars Market; 12.19. France Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million); 12.20. France Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million); 12.21. France Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million); 12.22. France Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
13. Eastern Europe Market: 13.1.1. Summary; 13.2. Market Overview; 13.2.1. Region Information; 13.2.2. Market Information; 13.2.3. Background Information; 13.2.4. Government Initiatives; 13.2.5. Regulations; 13.2.6. Regulatory Bodies; 13.2.7. Major Associations; 13.2.8. Taxes Levied; 13.2.9. Corporate Tax Structure; 13.2.10. Investments; 13.2.11. Major Companies; 13.3. Eastern Europe Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million); 13.4. Eastern Europe Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million); 13.5. Eastern Europe Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million); 13.6. Eastern Europe Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million); 13.7. Eastern Europe Biosimilars Market: Country Analysis; 13.8. Russia Biosimilars Market; 13.9. Russia Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million); 13.10. Russia Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million); 13.11. Russia Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million); 13.12. Russia Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
14. North America Market: 14.1.1. Summary; 14.2. Market Overview; 14.2.1. Region Information; 14.2.2. Market Information; 14.2.3. Background Information; 14.2.4. Government Initiatives; 14.2.5. Regulations; 14.2.6. Regulatory Bodies; 14.2.7. Major Associations; 14.2.8. Taxes Levied; 14.2.9. Corporate tax structure; 14.2.10. Investments; 14.2.11. Major Companies; 14.3. North America Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million); 14.4. North America Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million); 14.5. North America Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million); 14.6. North America Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million); 14.7. North America Biosimilars Market: Country Analysis; 14.8. USA Market; 14.8.1. Summary; 14.9. Market Overview; 14.9.1. Country Information; 14.9.2. Market Information; 14.9.3. Background Information; 14.9.4. Government Initiatives; 14.9.5. Regulations; 14.9.6. Regulatory Bodies; 14.9.7. Major Associations; 14.9.8. Taxes Levied; 14.9.9. Corporate Tax Structure; 14.9.10. Investments; 14.9.11. Major Companies; 14.10. USA Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million); 14.11. USA Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million); 14.12. USA Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million); 14.13. USA Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
15. South America Market: 15.1.1. Summary; 15.2. Market Overview; 15.2.1. Region Information; 15.2.2. Market Information; 15.2.3. Background Information; 15.2.4. Government Initiatives; 15.2.5. Regulatory Bodies; 15.2.6. Regulations; 15.2.7. Major Associations; 15.2.8. Taxes Levied; 15.2.9. Corporate Tax Structure; 15.2.10. Investments; 15.2.11. Major Companies; 15.3. South America Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million); 15.4. South America Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million); 15.5. South America Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million); 15.6. South America Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million); 15.7. South America Biosimilars Market: Country Analysis; 15.8. Brazil Biosimilars Market; 15.9. Brazil Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million); 15.10. Brazil Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million); 15.11. Brazil Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million); 15.12. Brazil Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
16. Middle East Market: 16.1.1. Summary; 16.2. Market Overview; 16.2.1. Region Information; 16.2.2. Market Information; 16.2.3. Background information; 16.2.4. Government Initiatives; 16.2.5. Regulatory Bodies; 16.2.6. Regulations; 16.2.7. Major Associations; 16.2.8. Taxes Levied; 16.2.9. Corporate Tax Structure; 16.2.10. Investments; 16.2.11. Major Companies; 16.3. Middle East Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million); 16.4. Middle East Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million); 16.5. Middle East Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million); 16.6. Middle East Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
17. Africa Market: 17.1.1. Summary; 17.2. Market Overview; 17.2.1. Region Information; 17.2.2. Market Information; 17.2.3. Background Information; 17.2.4. Government Initiatives; 17.2.5. Regulations; 17.2.6. Regulatory Bodies; 17.2.7. Major Associations; 17.2.8. Taxes Levied; 17.2.9. Corporate Tax Structure; 17.2.10. Investments; 17.2.11. Major Companies; 17.3. Africa Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million); 17.4. Africa Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million); 17.5. Africa Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million); 17.6. Africa Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
18. Competitive Landscape And Company Profiles: 18.1. Company Profiles; 18.2. Amgen Inc.; 18.2.1. Company Overview; 18.2.2. Products And Services; 18.2.3. Business Strategy; 18.2.4. Financial Overview; 18.3. Pfizer Inc.; 18.3.1. Company Overview; 18.3.2. Products And Services; 18.3.3. Business Strategy; 18.3.4. Financial Overview; 18.4. Novartis AG; 18.4.1. Company Overview; 18.4.2. Products And Services; 18.4.3. Business Strategy; 18.4.4. Financial Overview; 18.5. Samsung Bioepis Co., Ltd.; 18.5.1. Company Overview; 18.5.2. Products And Services; 18.5.3. Business Strategy; 18.5.4. Financial Overview; 18.6. Viatris Inc.; 18.6.1. Company Overview; 18.6.2. Products And Services; 18.6.3. Business Strategy; 18.6.4. Financial Overview
19. Pipeline Analysis
20. Key Mergers And Acquisitions In The Biosimilars Market: 20.1. Fresenius Kabi Acquired mAbxience; 20.2. Biocon Biologics to Acquire Viatris Biosimilars Business; 20.3. AbCellera Acquired TetraGenetics; 20.4. Celltrion Acquired Assets Of Takeda Pharmaceuticals; 20.5. Ligand Pharmaceuticals Acquired Pfenex; 20.6. ChrysCapital Acquired Stakes In Intas Pharmaceuticals; 20.7. Amgen Acquired Japanese JV with Astellas; 20.8. True North Acquired Stake In Biocon Biologics Ltd.; 20.9. Biocon Acquired Research and Development (R&D) Facility from Pfizer Healthcare India; 20.10. PAG Acquired Hisun BioRay Bio-pharmaceutical Co., Ltd.; 20.11. Pfizer Inc. Acquired Array BioPharma Inc.; 20.12. Samsung Bioepis Enters Into An Agreement With C-Bridge Capital; 20.13. Fuji Pharma Co., Ltd. Acquired Stake In Alvotech; 20.14. Kashiv Pharma Acquired Adello Biologics; 20.15. Bristol-Myers Squibb Acquired Celgene Corporation; 20.16. Takeda Pharmaceutical Company Limited Acquired Shire Plc; 20.17. Amneal Pharmaceuticals Merge With Impax Laboratories; 20.18. Biocon Merged With Sandoz
21. Global Biosimilars Market Opportunities And Strategies: 21.1. Global Biosimilars Market In 2026 – Countries Offering Most New Opportunities; 21.2. Global Biosimilars Market In 2026 – Segments Offering Most New Opportunities; 21.3. Global Biosimilars Market In 2026 – Growth Strategies; 21.3.1. Market Trend Based Strategies; 21.3.2. Competitor Strategies
22. Biosimilars Market, Conclusions And Recommendations: 22.1. Conclusions; 22.2. Recommendations; 22.2.1. Product; 22.2.2. Place; 22.2.3. Price; 22.2.4. Promotion; 22.2.5. People
23. Appendix: 23.1. Market Data Sources; 23.2. Research Methodology; 23.3. Currencies; 23.4. The Business Research Company
24. Copyright and Disclaimer